Lilly CEO, In Shanghai, Predicts Better Patent Protection Will Unleash Scientific Innovation Across China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Calling the start of the new millennium "the century of human medicine," John Lechleiter, Eli Lilly's chief executive officer, predicted that Chinese scientists would help shape the era, but also said that the government needs to advance its intellectual property regime in order to unleash innovation
You may also be interested in...
After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials
After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China